重组人脑利钠肽治疗急性失代偿性心力衰竭的效果  

Effect of Recombinant Human Brain Natriuretic Peptide treating acute decompensated heart failure

作　　者：郭敏[1] 

机构地区：[1]淄博矿业集团有限责任公司中心医院老年科,山东淄博255120

出　　处：《中国当代医药》2017年第17期130-132,共3页China Modern Medicine

摘　　要：目的探讨重组人脑利钠肽治疗急性失代偿性心力衰竭的效果。方法选取2015年5月~2016年5月我院收治的100例急性失代偿性心力衰竭患者,将其采用抽签法进行分组,每组50例。对照组和观察组分别采用单硝酸异山梨酯治疗和重组人脑利钠肽治疗,比较两组患者的6 min步行距离、24 h尿量、呼吸频率、心率和心功能指标。结果观察组患者的6 min步行距离[(114.69±6.89)m]、24 h尿量[(2458.32±68.58)ml]、呼吸频率[(18.65±1.54)次/min]、心率[(74.56±2.65)次/min]、LVEDD[(60.96±2.02)mm]、LVESD[(46.36±1.38)mm]、LVEF[(46.36±1.38)%]优于对照组的6 min步行距离[(85.43±5.32)m]、24 h尿量[(1453.28±11.58)ml]、呼吸频率[(24.31±1.05)次/min]、心率[(84.62±3.44)次/min]、LVEDD[(65.54±1.83)mm]、LVESD[(55.68±1.62)mm]、LVEF[(43.46±1.84)%](P<0.05)。结论重组人脑利钠肽治疗急性失代偿性心力衰竭的效果显著。Objective To explore the effect of Recombinant Human Brain Natriuretic Peptide treating acute decompensated heart failure.Methods 100 patients with acute decompensated heart failure treated in our hospital from May 2015 to May 2016 were selected and they were divided into the two groups using the lottery method,and there were 50 patients in each group.The control group and observation group was treated by Isosorbide Mononitrate and Recombinant Human Brain Natriuretic Peptide.6-minute walking distance,24-hour urine output,respiratory rate,heart rate and the cardiac function indexes were compared between the two groups.Results 6-minute walking distance [（114.69±6.89） m],24-hour urine output [（2458.32±68.58） ml],respiratory rate [（18.65±1.54） times/min],heart rate [（74.56±2.65） times/min],LVEDD[（60.96±2.02） mm],LVESD [（46.36±1.38） mm],LVEF [（46.36±1.38）%] were better than those of control group [（85.43±5.32） m,（1453.28±11.58） ml,（24.31±1.05） times/min,（84.62±3.44） times/min,（65.54±1.83） mm,（55.68±1.62） mm,（43.46±1.84）%]（P〈0.05）.Conclusion The effect of Recombinant Human Brain Natriuretic Peptide treating acute decompensated heart failure is significant.

关 键 词：重组人脑利钠肽 急性失代偿性心力衰竭 单硝酸异山梨酯 

分 类 号：R541.6[医药卫生—心血管疾病]